BPMC 241018 90.00P (BPMC241018P90000) Stock Options, News & Quotes

US OptionsDetailed Quotes

BPMC241018P90000

Watchlist

3.00
-0.80-21.05%

15min DelayClose Oct 4 16:00 ET

3.00High3.00Low

Intraday

5D
Daily

News

Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing
MT Newswires17:13 ET
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
Simply Wall StSep 27 13:01 ET
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Moomoo NewsSep 19 20:32 ET · Ratings
Blueprint Announces the Hiring of Industry Veteran John Smelter to Medical Outpatient Team
PR NewswireSep 12 18:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
PR NewswireSep 10 08:00 ET
Blueprint Medicines Corporation's (NASDAQ:BPMC) Business Is Yet to Catch Up With Its Share Price
Simply Wall StSep 6 08:25 ET

Comments

Stock_Drift

Apr 11 20:13

Extended Hours Top Moovers.

$Gryphon Digital Mining (GRYP.US)$ $Zimmer Biomet Holdings (ZBH.US)$ $Cohu Inc (COHU.US)$ $Evolv Technologies (EVLV.US)$ $Brookfield (BN.US)$ $VACASA INC (VCSA.US)$ $Blueprint Medicines (BPMC.US)$ $Williams-Sonoma (WSM.US)$ $U.S. Century Bank (USCB.US)$
📊⚡️📊

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Mar 15 06:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

Feb 19 12:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

Jan 29 09:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.

Blueprint Medicines Corporation's (NASDAQ:BPMC) Shareholders Might Be Looking For Exit